Principal products and services include integrated systems for specimen collection; an extensive line of safety-engineered blood collection products and systems; plated media; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and HAIs; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; and rapid diagnostic assays.
BD Diagnostics focuses on improving health outcomes for patients and providing laboratories with solutions that elevate quality, reduce costs, guide medical decisions and enhance the productivity of laboratory systems. Developing products that effectively integrate laboratory work processes, diagnostic testing procedures and information management is central to our business.
Preanalytical Systems focuses on specimen collection and accelerating growth through continued emphasis on safety, where innovation has led to second- and third-generation safety-engineered products offering greater protection and improved functionality. The conversion of emerging markets to evacuated tubes is also a priority.
Looking ahead, we are concentrating on new opportunities driven by emerging technologies – including molecular diagnostics and proteomics – and look to build our sample collection, stabilization and processing capabilities in these areas.
Diagnostic Systems continues to be a leader in microbiology and infectious disease diagnostics. Our focus on growth media – for both the clinical and industrial market segments – is the foundation of strong customer relationships and an entry point for instrument platforms. Our BD BACTEC and BD Phoenix Systems are important tools for microbiologists seeking clinically relevant answers for patients with life-threatening infections. The information these instruments provide is transferred to the BD Epicenter Microbiology Data Management System, which can alert physicians, infection control personnel and pharmacists who may need to take immediate action.
BD GeneOhm assays offer customers a menu of molecular diagnostics to rapidly identify some microorganisms that cause HAIs, such as the deadly strains of MRSA (methicillin-resistant Staphylococcus aureus). BD’s molecular diagnostics instruments, the BD ProbeTec and BD Viper Systems, used with our DNA-amplified assays, also help hundreds of laboratories worldwide detect sexually transmitted diseases. They provide reliable information that physicians need to make early diagnoses and use state-of-the-art automation to boost laboratory efficiency.
Our TriPath platform develops, manufactures and markets innovative solutions to improve the clinical management of cancer.
Looking forward, we plan to build on our unique instrument product portfolio and engineering capabilities to provide a range of systems to rapidly diagnose infectious diseases and detect cancer earlier.